Finance

Lists
Why is GLENMARK up 4,60%?
Dive Deeper
GLENMARK:NSE
Glenmark Pharmaceuticals Ltd
₹2 293,00
+4,60%
(+100,80) 1D
9 Okt., 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for GLENMARK...
Open
₹2 207,00
High
₹2 293,00
Low
₹2 203,00
Mkt. cap
647,14 mjd
Avg. vol.
588,18 k
Volume
414,34 k
Dividend
0,22%
Quarterly dividend
₹1,25
Ex-dividend date
03 Okt. 2025
P/E ratio
36,01
52-wk high
₹2 537,60
52-wk low
₹1 792,60
EPS
₹63,68
Shares outstanding
0,00
No. of employees
17 k
Open
₹2 207,00
High
₹2 293,00
Low
₹2 203,00
Mkt. cap
647,14 mjd
Avg. vol.
588,18 k
Volume
414,34 k
Dividend
0,22%
Quarterly dividend
₹1,25
Ex-dividend date
03 Okt. 2025
P/E ratio
36,01
52-wk high
₹2 537,60
52-wk low
₹1 792,60
EPS
₹63,68
Shares outstanding
0,00
No. of employees
17 k
News stories
From web sources and news partners
Profile
Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company based in Mumbai. Founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer, it is listed on the Bombay Stock Exchange and the National Stock Exchange of India. The company produces and distributes medicines in more than 80 countries, with operations concentrated in India, North America, Europe, and emerging markets. As of March 2026, it employed approximately 17,000 people. Its name derives from Saldanha's sons, Glenn and Mark. Wikipedia
About Glenmark Pharmaceuticals Ltd
CEO-
Employees16,9 k
Founded18 Nov. 1977
Headquarters-
SectorPharmaceutical industry
Websiteglenmarkpharma.com
Last report
03 Aug. 2026
Fiscal period
Q1 2027
EPS / Est. (INR)
₹17,11 / ₹17,30
-1,10%miss
Revenue / Est. (INR)
40,18 mjd / 39,17 mjd
+2,60%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
60,47 mjd
39,01 mjd
38,31 mjd
40,18 mjd
Cost of goods sold
12,65 mjd
12,95 mjd
13,65 mjd
12,46 mjd
Cost of revenue
12,65 mjd
12,95 mjd
13,65 mjd
12,46 mjd
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10,86 mjd
8,41 mjd
16,49 mjd
9,35 mjd
Operating expense
25,64 mjd
18,90 mjd
17,91 mjd
21,41 mjd
Total operating expenses
38,29 mjd
31,85 mjd
31,56 mjd
33,87 mjd
Operating income
22,18 mjd
7,15 mjd
6,75 mjd
6,32 mjd
Other non operating income
2,01 mjd
444,65 m
-2,72 mjd
657,64 m
EBT including unusual items
9,67 mjd
5,34 mjd
3,88 mjd
6,43 mjd
EBT excluding unusual items
23,53 mjd
7,18 mjd
7,61 mjd
6,43 mjd
Income tax expense
3,57 mjd
1,31 mjd
864,49 m
1,61 mjd
Effective tax rate
36,90%
24,49%
22,29%
24,96%
Other operating expenses
13,37 mjd
8,94 mjd
-55,65 m
10,33 mjd
Net income
6,10 mjd
4,03 mjd
3,01 mjd
4,83 mjd
Net profit margin
10,09%
10,34%
7,87%
12,02%
Earnings per share
-
19,21
20,96
17,11
Interest and investment income
-
-
413,36 m
-
Interest expense
-664,63 m
-414,32 m
-426,04 m
-539,97 m
Net interest expenses
-664,63 m
-414,32 m
-12,68 m
-539,97 m
Depreciation and amortization charges
1,41 mjd
1,54 mjd
1,48 mjd
1,73 mjd
EBITDA
23,54 mjd
7,80 mjd
7,80 mjd
7,75 mjd
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme